Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Molecules ; 28(18)2023 Sep 06.
Article in English | MEDLINE | ID: mdl-37764231

ABSTRACT

Lavender (Lavandula angustifolia Miller or Lavandula officinalis Chaix) is an ethnopharmacological plant commonly known as English lavender. Linalool and linalyl acetate are putative phytoactives in lavender essential oil (LEO) derived from the flower heads. LEO has been used in aroma or massage therapy to reduce sleep disturbance and to mitigate anxiety. Recently, an oral LEO formulation was administered in human clinical trials designed to ascertain its anxiolytic effect. However, human pharmacokinetics and an LC-MS/MS method for the measurement of linalool are lacking. To address this deficiency, a rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the analysis of linalool in human serum. Prior to the analysis, a simple sample preparation protocol including protein precipitation and liquid-liquid extraction of serum samples was created. The prepared samples were analyzed using a C18 reversed-phase column and gradient elution (acetonitrile and water, both containing 0.1% formic acid). A Waters Xevo TQ-S tandem mass spectrometer (positive mode) was used to quantitatively determine linalool and IS according to transitions of m/z 137.1→95.1 (tR 0.79 min) and 205.2→149.1 (tR 1.56 min), respectively. The method was validated for precision, accuracy, selectivity, linearity, sensitivity, matrix effects, and stability, and it was successfully applied to characterize the oral pharmacokinetics of linalool in humans. The newly developed LC-MS/MS-based method and its application in clinical trial serum samples are essential for the characterization of potential pharmacokinetic and pharmacodynamic interactions.


Subject(s)
Research Design , Tandem Mass Spectrometry , Humans , Chromatography, Liquid , Acyclic Monoterpenes
2.
J Pediatric Infect Dis Soc ; 7(2): e40-e42, 2018 May 15.
Article in English | MEDLINE | ID: mdl-29771385

ABSTRACT

We examined clinical outcomes for 53 young infants (<3 months of age) treated with outpatient parenteral antimicrobial therapy after discharge from a freestanding children's hospital. None of the patients experienced treatment failure or disease progression; 9% of them experienced a catheter-related complication, but this percentage is not different than that for older children.


Subject(s)
Ambulatory Care , Anti-Infective Agents/administration & dosage , Administration, Intravenous , Bacterial Infections/drug therapy , Herpes Simplex/drug therapy , Hospitals, Pediatric , Humans , Infant , Infant, Newborn , Length of Stay , Retrospective Studies , Treatment Outcome , Utah
3.
Pediatrics ; 130(1): e16-24, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22732178

ABSTRACT

OBJECTIVE: Febrile infants in the first 90 days may have life-threatening serious bacterial infection (SBI). Well-appearing febrile infants with SBI cannot be distinguished from those without by examination alone. Variation in care resulting in both undertreatment and overtreatment is common. METHODS: We developed and implemented an evidence-based care process model (EB-CPM) for the management of well-appearing febrile infants in the Intermountain Healthcare System. We report an observational study describing changes in (1) care delivery, (2) outcomes of febrile infants, and (3) costs before and after implementation of the EB-CPM in a children's hospital and in regional medical centers. RESULTS: From 2004 through 2009, 8044 infants had 8431 febrile episodes, resulting in medical evaluation. After implementation of the EB-CPM in 2008, infants in all facilities were more likely to receive evidence-based care including appropriate diagnostic testing, determination of risk for SBI, antibiotic selection, decreased antibiotic duration, and shorter hospital stays (P < .001 for all). In addition, more infants had a definitive diagnosis of urinary tract infection or viral illness (P < .001 for both). Infant outcomes improved with more admitted infants positive for SBI (P = .011), and infants at low risk for SBI were more often managed without antibiotics (P < .001). Although hospital admissions were shortened by 27%, there were no cases of missed SBI. Health Care costs were also reduced, with the mean cost per admitted infant decreasing from $7178 in 2007 to $5979 in 2009 (-17%, P < .001). CONCLUSIONS: The EB-CPM increased evidence-based care in all facilities. Infant outcomes improved and costs were reduced, substantially improving value.


Subject(s)
Fever/therapy , Hospital Costs , Infant Care/organization & administration , Outcome and Process Assessment, Health Care , Quality Improvement , Anti-Bacterial Agents/therapeutic use , Bacteremia/complications , Bacteremia/diagnosis , Bacteremia/economics , Bacteremia/therapy , Clinical Protocols , Cohort Studies , Cost-Benefit Analysis , Female , Fever/economics , Fever/etiology , Humans , Infant , Infant, Newborn , Length of Stay/statistics & numerical data , Linear Models , Logistic Models , Male , Meningitis, Bacterial/complications , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/economics , Meningitis, Bacterial/therapy , Program Evaluation , Urinary Tract Infections/complications , Urinary Tract Infections/diagnosis , Urinary Tract Infections/economics , Urinary Tract Infections/therapy , Utah , Virus Diseases/complications , Virus Diseases/diagnosis , Virus Diseases/economics , Virus Diseases/therapy
SELECTION OF CITATIONS
SEARCH DETAIL